LF
INKT icon

Longbow Finance’s MiNK Therapeutics INKT Stock Holding History

Longbow Finance’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Hold
16,667
– – 0.02% 59
2026
Q1 		$176K Hold
16,667
– – 0.03% 55
2025
Q4 		$186K Hold
16,667
– – 0.03% 61
2025
Q3 		$233K Hold
16,667
– – 0.02% 68
2025
Q2 		$123K Hold
16,667
– – 0.01% 70
2025
Q1 		$144K Hold
16,667
– – 0.02% 79
2024
Q4 		$116K Hold
16,667
– – 0.01% 71
2024
Q3 		$125K Hold
16,667
– – 0.01% 86
2024
Q2 		$158K Hold
16,667
– – 0.02% 84
2024
Q1 		$151K Hold
16,667
– – 0.02% 83
2023
Q4 		$178K Buy
+16,667
New +$174K 0.02% 62
2023
Q2 		– Sell
-16,667
Closed -$316K – 62
2023
Q1 		$316K Hold
16,667
– – 0.04% 59
2022
Q4 		$435K Buy
+16,667
New +$391K 0.06% 56

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

Longbow Finance's INKT Position: Q2 2026 in Review

Longbow Finance held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 16,667 shares worth $195K. The position accounts for 0.02% of the portfolio, ranked #59.

Longbow Finance first reported a position in INKT in Q4 2022 and has held it in 13 quarters since. The position peaked at $435K in Q4 2022. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Longbow Finance held 16,667 shares of MiNK Therapeutics worth $195K as of Q2 2026.
  • Longbow Finance left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up 0.02% of Longbow Finance's portfolio in Q2 2026, its #59 holding.
  • Longbow Finance first reported a position in MiNK Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Longbow Finance's MiNK Therapeutics position peaked at $435K in Q4 2022.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Longbow Finance's 13F filing for Q2 2026, filed 29 Jul 2026.